Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial Carcinoma

NCT05112601 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05112601
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05112601 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial Carcinoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Recruiting
Start date
June 2, 2022
Completion date
July 30, 2032
Enrollment
81 (estimated)
Sites
138

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial adenocarcinoma, endometrial clear cell adenocarcinoma, endometrial dedifferentiated carcinoma, endometrial endometrioid adenocarcinoma, endometrial mixed cell adenocarcinoma, endometrial mucinous adenocarcinoma, endometrial undifferentiated carcinoma, endometrioid adenocarcinoma, recurrent endometrial carcinoma